ID   RPMI-SE
AC   CVCL_A0HT
DR   Wikidata; Q123033384
RX   PubMed=4057430;
RX   PubMed=7591954;
CC   Population: Caucasian.
CC   Doubling time: 24 hours (PubMed=4057430).
CC   Karyotypic information: Hypertetraploid (PubMed=4057430).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   35Y
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 30-01-24; Version: 2
//
RX   PubMed=7591954; DOI=10.1111/j.1349-7006.1995.tb03087.x; PMCID=PMC5920923;
RA   Kinoshita, Hidefumi
RA   Yamada, Hitoshi
RA   Ogawa, Osamu
RA   Kakehi, Yoshiyuki
RA   Osaka, Mitsuhiko
RA   Nakamura, Eijiro
RA   Mishina, Mutsuki
RA   Habuchi, Tomonori
RA   Takahashi, Rei
RA   Sugiyama, Taketoshi
RA   Yoshida, Osamu
RT   "Contribution of chromosome 9p21-22 deletion to the progression of
RT   human renal cell carcinoma.";
RL   Jpn. J. Cancer Res. 86:795-799(1995).
//
RX   PubMed=4057430; DOI=10.1016/S0022-5347(17)47710-x;
RA   Goldrosen, Martin H.
RA   Huben, Robert
RA   Miller, Glenn A.
RA   Lewis, David A.
RA   Ochi, Hisako
RA   Sandberg, Avery Aba
RA   Pontes, Jose Edson
RT   "Characterization of a renal cell carcinoma cell line suitable as a
RT   target for immunological studies in vitro and in the nu/nu mouse.";
RL   J. Urol. 134:1271-1275(1985).
//